October 9, 2019 09:35 AM EDTUpdated October 10, 04:33 AM
Deals
R&D

Part­ner Bay­er push­es Ion­is' an­tithrom­bot­ic drug in­to mid-stage de­vel­op­ment

Natalie Grover

Reporter

In 2015, when Io­n­is Phar­ma­ceu­ti­cals car­ried the ill-fat­ed name of Isis Phar­ma­ceu­ti­cals, it grant­ed Bay­er the li­cense to de­vel­op its pro­grams tar­get­ing Fac­tor XI …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times